infliximab-qbtx
E850384
Infliximab-qbtx is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
All labels observed (1)
| Label | Occurrences |
|---|---|
| infliximab-qbtx canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10214642 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: infliximab-qbtx Context triple: [Ixifi, hasActiveSubstance, infliximab-qbtx]
-
A.
infliximab-dyyb
Infliximab-dyyb is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
B.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
C.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
D.
Humira
Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
-
E.
Remicade
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: infliximab-qbtx Target entity description: Infliximab-qbtx is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
A.
infliximab-dyyb
Infliximab-dyyb is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
B.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
C.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
D.
Humira
Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
-
E.
Remicade
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biosimilar medicinal product
ⓘ
monoclonal antibody ⓘ tumor necrosis factor alpha inhibitor ⓘ |
| adverseEffect |
abdominal pain
ⓘ
headache ⓘ infusion-related reactions ⓘ nausea ⓘ rash ⓘ upper respiratory tract infection ⓘ |
| belongsToPharmacologicClass |
biologic disease-modifying antirheumatic drug
ⓘ
immunosuppressant ⓘ |
| belongsToRegulatoryCategory | prescription-only medicine ⓘ |
| belongsToTherapeuticArea |
dermatology
ⓘ
gastroenterology ⓘ rheumatology ⓘ |
| contraindication |
moderate to severe heart failure
ⓘ
severe active infection ⓘ |
| effect |
induces and maintains clinical remission in inflammatory bowel disease
ⓘ
reduces signs and symptoms of inflammation ⓘ |
| hasAdministrationPattern | induction and maintenance dosing schedule ⓘ |
| hasATCClass | L04AB02 ⓘ |
| hasEffectOn |
immune system modulation
ⓘ
pro-inflammatory cytokine activity ⓘ |
| hasImmunoglobulinType | IgG1 ⓘ |
| hasMolecularType | chimeric monoclonal antibody ⓘ |
| hasRouteOfAdministration | intravenous infusion ⓘ |
| hasTarget | tumor necrosis factor alpha NERFINISHED ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isBiosimilarOf | infliximab NERFINISHED ⓘ |
| isIntendedFor | adult patients ⓘ |
| mayBeUsedIn | pediatric patients for certain indications ⓘ |
| mechanismOfAction |
binds to soluble and transmembrane TNF-alpha
ⓘ
inhibits TNF-alpha mediated inflammatory signaling ⓘ |
| requiresMonitoring |
complete blood count
ⓘ
liver function tests ⓘ signs and symptoms of infection ⓘ |
| requiresScreeningBeforeUse |
hepatitis B virus infection
ⓘ
latent tuberculosis infection ⓘ |
| usedFor |
Crohn’s disease
NERFINISHED
ⓘ
ankylosing spondylitis ⓘ plaque psoriasis ⓘ psoriatic arthritis ⓘ rheumatoid arthritis ⓘ ulcerative colitis ⓘ |
| warning |
risk of hepatitis B virus reactivation
ⓘ
risk of malignancies including lymphoma ⓘ risk of reactivation of latent tuberculosis ⓘ risk of serious infections ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: infliximab-qbtx Description of subject: Infliximab-qbtx is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.